Editorial Type: Original Research
 | 
Online Publication Date: 08 Sept 2025

Effects of Long-Term Carprofen and Omeprazole Administration in C57BL/6J Mice

DVM, MS,
DVM, MS, DACVP, and
MD, FACP, FACR
Article Category: Research Article
Page Range: 1 – 7
DOI: 10.30802/AALAS-JAALAS-25-069
Save
Download PDF

Osteoarthritis is the leading cause of disability in the United States and affects approximately half of adults over the age of 65. Many osteoarthritis patients take nonsteroidal anti-inflammatory drugs (NSAIDs) on a long-term basis, often concurrently with proton pump inhibitors (PPIs), such as omeprazole, to prevent gastric ulceration. Mice (Mus musculus) are a commonly used animal model of osteoarthritis. There are little data regarding long-term administration of NSAIDs or coadministration of PPIs and NSAIDs in mice. This study sought to determine if administration of carprofen, a commonly used veterinary NSAID, has adverse effects when administered for 21 days and if coadministration of omeprazole reduces the incidence of adverse effects. Four groups of C57BL/6J male (n = 5/group) and female (n = 5/group) mice were weighed daily and administered 10 mg/kg carprofen and 8.2 mg/kg omeprazole, 10 mg/kg carprofen, 8.2 mg/kg omeprazole, or control suspension once daily by oral gavage for 21 days. All mice were euthanized, and complete blood count (CBC), serum chemistry, fecal occult blood, and pyloric histopathology and gastritis scoring were conducted. All animals remained clinically healthy for the duration of the study. White blood cell counts (WBCs) and platelets were significantly lower in the carprofen and omeprazole group. Neutrophil counts were significantly lower in the carprofen and omeprazole and the carprofen groups. Compared with the control group, albumin was significantly higher in the carprofen group. Fecal occult blood tests were negative for all animals. No animals had pyloric mucosal ulceration, and gastritis scores were not significantly different between groups. Body weight significantly decreased for all groups over time, with no significant differences among treatment groups. Carprofen and omeprazole may be safely administered to C57BL/6J mice for 21 days but may induce significant changes in CBC and serum chemistry.

Copyright: © American Association for Laboratory Animal Science 2025
<bold>Figure 1.</bold>
Figure 1.

Experimental Groups and Study Design.


<bold>Figure 2.</bold>
Figure 2.

Significant CBC and chemistry changes by treatment group. (A) Serum albumin by treatment group. (B) WBC count by treatment group. (C) Neutrophil count by treatment group. (D) Platelet count by treatment group. Summary data are represented as mean ± SD for platelets and WBCs. Data are represented as median ± IQR for albumin and neutrophils. c, carprofen; c+o, carprofen + omeprazole; o, omeprazole. *P ≤ 0.05 and +P ≤ 0.005.


<bold>Figure 3.</bold>
Figure 3.

Pylorus Histopathology and Gastritis Scoring (H&E stain). (A) Gastritis score 0: sagittal section of normal pyloric region with pyloroduodenal junction visible; 4× magnification. (B) Gastritis score 1: mild neutrophilic infiltrate in lamina propria (circle); 40× magnification. (C) Gastritis score 2: mild surface erosion (arrow); minimal neutrophils within lamina propria (circle); 40× magnification. (D) Gastritis score 3: mild surface erosion (arrow); small to moderate numbers of neutrophils in the lamina propria (circle) and submucosa (star); 20× magnification.


<bold>Figure 4.</bold>
Figure 4.

Gastritis Scores by Treatment Group. Data represented as median ± IQR. c, carprofen; c+o, carprofen + omeprazole; o, omeprazole.


<bold>Figure 5.</bold>
Figure 5.

Weight over time by sex and treatment group. (A) Mean male weight ± SD by treatment group. (B) Mean female weight ± SD by treatment group. Weights by treatment group were analyzed using 2-way ANOVA, with male and female weights analyzed separately.


Contributor Notes

Corresponding author. Email: abby-bernardini@ouhsc.edu
Received: 24 Apr 2025
Accepted: 21 Aug 2025
  • Download PDF